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Abstract
Background: Aggregatable amyloid b-peptide (Ab) and non-aggregatable p3-Alca are metabolic products of the g-
secretase cleavage of amyloid b-protein precursor (APP) and Alcadeina (Alca), respectively. Familial AD (FAD) -linked
mutations in the presenilin 1 or 2 (PS1 or PS2) component of g-secretase can cause alternative intramembranous
processing of APP and Alca, leading to a coordinated generation of variants of both Ab and p3-Alca. Variant Alca
peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic
Alzheimer’s disease (AD). Since, like APP, Alca is largely expressed in brain, one might predict that alternative processing
of Alca would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple g-secretase
substrates might define an endophenotype of p3-Alca, in whom AD is due either to dysfunction of g-secretase or to a
disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains.
Results: We developed a simple procedure for extraction of p3-Alca from plasma and for analyzing this extract in
a sensitive, p3-Alca-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alca levels
and Ab40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of
these patients, levels of plasma p3-Alca were significantly higher, and were accompanied by parallel changes in
Ab40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not
observed in subjects with frontotemporal lobar degeneration (FTLD).
Conclusion: Reagents and procedures have been established that enable extraction of p3-Alca from plasma and
for quantification of plasma p3-Alca levels by ELISA. Some populations of AD subjects apparently show increased
levels of both p3-Alca and Ab40. Quantification of p3-Alca level may be useful as a readily accessible biomarker
for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of g-
secretase or with a disorder of the clearance of transmembrane domain-derived peptides.
Background
Alcadein proteins (Alcs) represent a family of neuronal
type I transmembrane proteins composed of Alcadeina
(Alca), Alcadeinb (Alcb)a n dA l c a d e i n g (Alcg). The Alcs
are encoded by three independent genes that are highly
conserved among mammals, as is the gene encoding the
Alzheimer’s amyloid b-protein precursor (APP). Alcs
and APP are largely co-localized in brain neurons where
they are also frequently cross-linked by the X11L adap-
tor. Both Alc and APP accumulate in the dystrophic
neurites surrounding senile plaques of Alzheimer’sd i s -
ease (AD) brain and participate in the molecular patho-
biology of the disease [1-5]. Although Alcs undergo
alternative processing in sporadic AD [5], our data
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observations), and Alcs do not appear in amyloid depos-
its [1].
Both APP and the Alcs are substrates for primary pro-
teolytic cleavage by the APP a-secretases ADAM10 and
ADAM17. These cleavages are directed toward the holo-
proteins within their respective intralumenal juxtamem-
brane domains, causing shedding of the ectodomains
and retention of membrane-bound carboxyl terminal
fragments (CTFs) [4]. Next, the identical g-secretase can
cleave either the APP-CTF or the Alc-CTF within the
transmembrane region. This sequential a-a n dg-clea-
vage of APP yields the p3 peptide, and, by analogy, the
a-a n dg-cleavage of Alc generates the p3-Alc peptide
(amino acid sequence of p3-Alca along with Ab and p3
are shown in Additional file 1, Figure S1A).
A substantial body of research has established that
pathogenic mutations in the presenilin 1 (PS1) and pre-
senilin 2 (PS2) genes underlie most familial Alzhemer’s
disease (FAD: [6]), and that PS1 or PS2 forms the cata-
lytic site of the g-secretase aspartyl proteinase complex
[7]. There are ~200 known pathogenic PS1/PS2 muta-
tions, and all are believed to act by shifting registration
of the intramembranous cleavage of APP within the cat-
alytic site of g-secretase so as to increase the ratio of the
level of the minor and more aggregation prone Ab spe-
cies (Ab42) relative to that of the major and less aggre-
gatable species (Ab40) (also known as the Ab42/40
ratio; [8,9]). While there is controversy around whether
PS mutations act by elevating Ab42, by decreasing
Ab40, or both, there is consensus around the concept
that increases in the Ab42/40 ratio are believed to lead
to AD by permitting the formation of neurotoxic Ab oli-
gomer(s) [10,11].
Recently, low cerebrospinal fluid (CSF) Ab42 [12,13]
and low plasma Ab42/40 [14-16] have been identified as
possible biomarkers for AD. Ab42 levels are determined
by a composite of Ab42 generation, aggregation, and
deposition. In order to study the role of g-secretase cata-
lysis apart from the effects of Ab42 aggregation, we [4,5]
and others [17] have studied metabolism of non-APP-
derived, nonamyloidogenic g-secretase reaction products.
Using a cell culture model, we have demonstrated that
Alca cleavage by g-secretase is modulated by a panel of
FAD-linked PS1 mutations, all of which increased the
proportionate representation of minor p3-Alca species
with variant C-termini [4]. Thus, we have proposed that
levels and/or ratios of p3-Alca species in CSF may have
clinical utility as surrogate markers of g-secretase dys-
function [5]. Conceivably, patients with AD due to g-
secretase dysfunction might be most likely to respond to
g-secretase modulator therapies.
Reduction in clearance of CSF Ab has recently been
associated with sporadic AD (SAD; [18]), a phenomenon
that might well be explained by Ab aggregation or oligo-
merization, since there is clear evidence that aggregated
Ab is cleared more slowly than non-aggregated forms. A
less likely, but not impossible, scenario that could lead
to elevated levels of Ab and p3-Alc species involves a
formulation wherein SAD might, in some cases, be attri-
butable to a defect in clearance of transmembrane (TM)
domain-derived peptides. This formulation would dove-
tail well with evidence that apolipoprotein E (APOE) iso-
type modulates Ab clearance [19,20] and raises the
possibility that APOE genotype may modulate clearance
of many TM domain-derived peptides, including Ab and
p3-Alc. In separate work still in progress, we are study-
ing whether there exists any relationship between APOE
genotype in the levels of plasma and CSF p3-Alc. In any
event, there is substantial support for the possibility that
alterations in Ab generation and/or clearance are con-
sidered to be possible underpinnings for at least some
cases of SAD. These alternative hypotheses are not
mutually exclusive and could underlie different bio-
chemical endophenotypes that all lead to clinical AD.
Here we report the establishment of the reagents and
procedures that will enable the extraction of p3-Alca
from plasma and the quantification of plasma p3-Alca
levels by ELISA. We also investigate the possibility that
quantification of plasma levels of both p3-Alca and
Ab40 may be useful as readily accessible biomarkers for
defining endophenotypes of sporadic AD that are asso-
ciated with either a dysfunction of g-secretase or with a
disorder of the clearance of TM domain-derived
peptides.
Results
Extraction and quantification of serum and plasma p3-
Alcs
Supplementary Figure S1A displays the amino acid
sequences and cleavage sites of human p3-Alca and Ab.
Non-aggregatable p3-Alc peptides are detectable in CSF
[4], and changes in their quality and quantity have been
proposed to represent evidence for g-secretase dysfunc-
tion in SAD ([5]; Hata et al submitted for publication).
Because circulating biomarkers offer advantages over
CSF biomarkers for noninvasive and/or serial sampling,
we sought to detect p3-Alca in serum and plasma.
In a pilot study, efforts focused on detecting endogen-
ous p3-Alca in serum. Healthy human serum (HS), new-
born calf serum (CS), fetal bovine serum (FBS) and
bovine serum albumin solution (BSA, 10 mg/mL in
PBS), or these same preparations containing synthetic
p3-Alca35 (10 ng) were subjected to immunoprecipita-
tion after samples were depleted of immunoglobulins by
pre-clearing with protein-G Sepharose beads (GE
Healthcare). The immunoprecipitates were probed by
Western blotting. Endogenous p3-Alca was detected in
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BSA solution. These data indicate that, at least some-
times, endogenous p3-Alca is detectable in serum (Addi-
tional file 1, Figure S1B).
Although endogenous p3-Alca was detectable in
serum, this fluid contained factor(s) that interfered with
the immunodetection of p3-Alca (Additional file 1, Fig-
ure S1B). When serum spiked with synthetic p3-Alca35
peptide (10 ng) was analyzed, a strong signal was
detected in the FBS and BSA solutions. However, p3-
Alca35 peptide was not initially detectable in HS or CS
even after spiking with synthetic p3-Alca35 peptide,
although overexposure of the film revealed a weak signal
in HS (Additional file 1, Figure S1B). Therefore, this
pilot study suggested that; (i) endogenous p3-Alc is pre-
sent in serum, but that (ii) serum contains factor(s)
other than IgG that interfere with one or more steps in
the immunoprecipitation/immunodetection protocol for
detecting either endogenous or exogenous p3-Alca.
Next, we developed an ELISA system that was specific
for p3-Alca. We established that this ELISA could detect
synthetic p3-Alca35 in aqueous buffer in the range of 39
to 625 pg/mL and did not cross-react with p3-Alcb37, a
p3-Alcb species derived from Alcb (Figure 1A). However,
this ELISA was not specific for p3-Alca35 since the
assay also detected the p3-Alca species p3-Alca39 (Fig-
ure 1B). Therefore, we concluded that the ELISA could
reliably be used to quantify the major total plasma p3-
Alca but the primary antibody was not p3-Alca variant-
specific.
We next examined whether synthetic p3-Alca35 in
human serum and plasma could be quantified by ELISA
(Figure 2). p3-Alca35 was dissolved in human serum
(left) or plasma (right), or in buffer A (closed diamonds),
and the samples were applied to ELISA plates. Although
h u m a ns e r u ma n dp l a s m aw e r ed i l u t e dt w o - f o l d( o p e n
triangles) and four-fold (open circles) with buffer A, or
left neat (closed squares), immunoreactivity to p3-
Alca35 was significantly suppressed under both these
buffer conditions (Figure 2A), as suggested by an immu-
noprecipitation study (Additional file 1, Figure S1B).
The yields of p3-Alca35 (present in serum at a concen-
tration of 625 pg/mL) were 51% (for neat samples), 60%
(for samples diluted two-fold) and 69% (for samples
diluted four-fold). The yields from a sample of plasma
containing 625 pg/mL were 60% (neat), 65% (two-fold
dilution) and 74% (four-fold dilution), respectively, when
compared with identical levels of p3-Alca35 that were
present in buffer A (closed diamonds).
This result confirmed that both adult serum and
plasma contained factor(s) that interfered with the
determination of p3-Alca by ELISA even following a
four-fold dilution (Figure 2A). This suggested to us that
chemical separation of p3-Alc with quantitative recovery
would be necessary to remove the interfering factor(s),
and therefore to optimize the assay of p3-Alc in plasma
or serum. A standard organic extraction protocol
(chloroform:methanol 2:1) was used to recover synthetic
p3-Alca35 peptide from neat samples of healthy human
serum (Figure 2B, left, squares) and plasma (Figure 2B,
right, squares). After using this extraction protocol to
pre-process samples, we observed a standard curve
whose slope was almost identical to that of the standard
curve in which identical amounts of the synthetic p3-
Alca35 peptide were dissolved in buffer A (closed
Figure 1 Specificity of sELISA. A.T h ei n d i c a t e da m o u n t s( 3 9t o
625 pg/ml) of synthetic p3-Alca35 (diamonds) and p3-Alcb37
(triangles) peptides were dissolved in buffer A (100 μL per well of a
96-well plate) and assayed with ELISA. B. The indicated amounts (39
to 625 pg/ml) of synthetic p3-Alca35 (diamonds) and p3-Alca39
(triangles) peptides were dissolved in buffer A (100 μL per well of a
96-well plate) and assayed with ELISA and cross-reactivity was
examined. The amino acid sequence information of p3-Alca35
(Additional file 1, Figure S1A) and p3-Alcb37 are described
previously (4, 5).
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the immunoreaction were largely excluded by the
chloroform:methanol extraction (see Materials and
Methods). This procedure resulted in yields (according
to ELISA) that were 82% for peptide (625 pg/mL) dis-
solved in serum (left) and 91% for that dissolved in
plasma (right) (Figure 2B), relative to the identical con-
centration of peptide dissolved in buffer A. Recovery of
p3-Alca35 from plasma via the extraction protocol was
high enough (> 90%) to be considered quantitative.
Once extraction conditions were established, we
turned to the measurement of endogenous p3-Alca
levels in serum and plasma from various clinical popu-
lations. Serum and plasma samples derived from the
same subjects (healthy normal, n = 5) were compared
for p3-Alca levels (Table 1). The p3-Alca levels in
serum samples were lower (67-87%) than those
observed in plasma samples, suggesting that 10 to 30%
of p3-Alca may be trapped in clots or degraded by the
proteases involving in clotting. Similar issues have also
plagued Ab ELISAs, and we therefore used plasma sam-
ples for analyzing the cohorts of subjects with various
neurological diagnoses.
Plasma p3-Alca levels in AD and FTLD subjects (Japanese
cohort 1)
As a first trial, we examined levels of p3-Alca,A b40,
and Ab42 levels in plasma from a cohort of patients
(designated “Japanese cohort 1”)w i t he i t h e rA D( n=
49) or FTLD (n = 15). There were no remarkable differ-
ences for p3-Alca,A b40, and Ab42 levels between AD
and FTLD subjects, except that there was a trend
toward higher plasma Ab40 values in some subjects
(Table 2and Additional file 1, Figure S2). In order to
characterize the “high Ab40 subjects” and “low Ab40
subjects” in further detail, a cut-off value of Ab40 (340
pg/mL, the average of Ab4 0v a l u ei nA Ds u b j e c t s ) ,w a s
imposed, and the p3-Alca,A b40 and Ab42 levels were
re-analyzed (Figure 3). When populations were stratified
by Ab40 levels ("low Ab40” indicates < 340 pg/mL;
“high Ab40” indicates > 340 pg/mL of middle panels of
Figure 3), the high Ab40 population was noted to con-
tain samples with a significantly higher Ab42 levels
when compared to the Ab42 levels from the low Ab40
population, and this was true in both AD (right of Fig-
u r e3 A )a n dF T L D( r i g h to fF i g u r e3 B )p o p u l a t i o n s .
There were no significant differences between the low
and high Ab40 populations with respect to age, Ab40/
42 ratio, and MMSE score distributions (Additional file
1, Figure S3). However, the p3-Alca levels were signifi-
cantly higher in high Ab40 samples when compared
with those present in low Ab40 samples (left of Figure
3A), indicating that levels of p3-Alca,A b40 and Ab42
were correlated in some subgroups. This coordinated
alteration in p3-Alca levels was observed in AD but not
in FTLD subjects despite of the covariance of Ab42 and
Ab40 levels in both populations (left of Figure 3B).
Figure 2 Effect of p3-Alca extraction from serum and plasma
on the quantification of p3-Alca with sELISA. A. Quantification of
p3-Alca35 peptide in human serum (left) and plasma (right) without
extraction. Synthetic p3-Alca35 peptide was dissolved in human
serum and plasma and the samples in the indicated concentrations,
and samples were assayed by ELISA alongside samples in which
standard p3-Alca35 peptide was dissolved in buffer A (closed
diamonds in each respective panel). The p3-Alca35 peptide was
added to undiluted serum or plasma [closed squares], or to serum
or plasma diluted 2-fold [open triangles] or 4-fold [open circles]
with buffer A. B. p3-Alca35 peptide was added to undiluted serum
(left) or plasma (right), and extracted using the procedure described
in “Materials and Methods “. Extracted samples (open squares in
panel B) were also examined alongside a standard p3-Alca35
peptide dissolved in buffer A (closed diamonds). Endogenous p3-
Alca levels in serum and plasma (no addition of synthetic p3-Alca)
were subtracted in order to determine the specific curve for
quantifying levels of synthetic p3-Alca.




Mean ± SD Mean ± SD
1 129 ± 3 148 ± 6
2 103 ± 8 154 ± 15
3 142 ± 2 165 ± 0
4 151 ± 24 178 ± 13
5 182 ± 12 245 ± 10
Serum and plasma samples were prepared from five non-AD healthy
volunteers respectively and p3-Alca was quantified with ELISA in duplicates
after extraction, as described in “Materials and Methods“. SD, standard
deviation.
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neurological disease” (OND) control, Japanese cohort 1
does not include non-demented subjects, and FTLD
subjects do not match AD subjects with regard to aver-
age age (Table 2), therefore, we next examined plasma
p3-Alca levels in Japanese cohort 2 which included age-
matched nondemented controls.
Plasma p3-Alca levels in AD and non-AD subjects
(Japanese cohort 2)
We examined p3-Alca levels in the extracted plasma of
a second group of AD subjects and age-matched elderly
nondemented controls (total n = 60). This cohort
included AD patients of CDR 2 and CDR 3, and these
AD patients showed relatively higher Ab40 levels (n =
39, 378 ± 113 pg/mL) in plasma when compared to
those from the age-matched normal control subjects (n
= 21, 254 ± 63 pg/mL) (Table 3). The plasma of these
AD subjects (n = 39, average age 76 ± 7) contained 232
± 59 pg/mL p3-Alca, while that of age-matched normal
controls (n = 21, average age 73 ± 6) contained 163 ±
70 pg/mL of p3-Alca (Table 3, Figure 4A, upper; P =
0.0017 by the Mann-Whitney U-test)). Surprisingly, the
statistical difference was largely restricted to female sub-
jects. The plasma from female AD subjects (n = 24)
contained 245 ± 58 pg/mL of p3-Alca, while that of
female elderly nondemented controls (n = 14) contained
142 ± 77 pg/mL (P = 0.0006) (Figure 4A, middle). In
contrast, plasma of male AD subjects (212 ± 54 pg/mL,
n = 15) and male elderly normal controls (205 ± 19 pg/








AD Total 49 75 ± 7 197 ± 50 335 ± 82 26 ± 7
Male 18 76 ± 6 193 ± 57 342 ± 77 28 ± 8
Female 31 75 ± 7 200 ± 47 331 ± 86 25 ± 7
FTLD Total 15 64 ± 12 190 ± 31 366 ± 51 30 ± 6
Male 8 65 ± 14 197 ± 20 371 ± 57 29 ± 7
Female 7 61 ± 9 183 ± 41 361 ± 47 31 ± 7
Average age, gender, and average values of p3-Alca,A b40 and Ab42 of AD
and FTLD subjects are summarized. Numbers indicate means ± standard
deviation. Details of individual subjects are shown in Additional file 2, Tables
S1 (AD) and S2 (FTLD).
Figure 3 Levels of p3-Alca and Ab in plasma from “low Ab40” and “high Ab40” populations of AD and FTLD subjects (Japanese
cohort 1). Subjects with AD and FTLD were separated into two populations, who showed low (< 340 pg/mL) and high (> 340 pg/ml) Ab40
levels (cut-off line is shown in the middle panels with dotted line). AD (A) and FTLD (B) are respectively indicated in two populations for p3-Alca
(left), Ab40 (middle) and Ab42 (right). Statistical analysis was performed using the Mann-Whitney U-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. N.
S, not significant.
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tistical significance was detected (Figure 4A, lower).
Unextracted plasma samples from this cohort were
also studied. Ab40 levels in AD subjects distributed
within a higher range than that observed for age-
matched normal controls (Figure 4B, upper). The higher
plasma Ab40 levels in female, but not male, AD subjects
were readily obvious to visual inspection (Figure 4B,
middle, lower). Levels of p3-Alca and Ab40 were
increased in parallel in AD subjects and were higher
than the levels observed in elderly normal controls.
The p3-Alca levels within a particular individual did
not substantially change when blood samples were taken
every 8 h over a 24 h period (Figure 5). Therefore, the
possibility that the time of day when blood was sampled
was excluded as a significant factor.
Correlation between levels of p3-Alca and Ab40
We anticipated that the level of non-aggregatable p3-
Alca in plasma might parallel that of Ab,a tl e a s tw i t h
regard to Ab4 0 ,w h i c hi sl e s sa g g r e g a t a b l et h a nA b42.
Therefore, we tested for the existence of any correlation
between levels of p3-Alca and those of Ab40 in Japanese
cohort 2. In AD subjects (n = 39), a significant correla-
tion was observed between levels of p3-Alca and Ab
(Figure 6A upper; r = 0.4405, P = 0.0050). However, this
strong correlation was restricted to samples from female
subjects (n = 24) (Figure 6A middle; r = 0.6149, P =
0.0014). No significant correlation was observed between
levels of p3-Alca and Ab in samples from male subjects
(n = 15) (Figure 6A, lower; r = 0.07328, P = 0.7952).
Analysis of levels of p3-Alca and Ab in samples from
normal subjects revealed that there was also a strong
correlation in normal subjects (n = 21) between levels of
these two peptides (Figure 6B, upper; r = 0.6275, P =
0.0023). The correlation between levels of p3-Alca and
Ab in samples from both normal females (n = 14) and
those from normal males (n = 7) was statistically signifi-
cant (for female subjects, Figure 6B, middle; r = 0.6117,
P = 0.0201: for male subjects, Figure 6B, lower; r =
0.7857, P = 0.0480). Overall, these analyses indicated
that there was a significant correlation between levels of
p3-Alca and those of Ab40 in the plasma of normal
subjects, and that this correlation was more robust in
the plasma of female AD subjects.
Discussion
The pathogenesis of sporadic AD is thought to be
genetically heterogeneous. The precise identities and
relative importance of the many contributory genes
remain unclear, and additional loci have recently been
identified [21]. This is in contrast to the situation for
FAD in which pathogenic mutations of APP and PS
genes cause alterations in Ab speciation [6,7].
From the analyses of p3-Alca levels in CSF, we pre-
viously proposed that alternative processing of multiple
g-secretase substrates may occurs in some sporadic AD
populations. This earlier study was performed using a
combination of immunoprecipitation and MALDI-TOF/
MS to isolate and quantify p3-Alc in 300 μLo fC S F
[4,5]. Although the procedure showed semi-quantitative
accuracy and was effective for testing changes in the
abundance of p3-Alc species in the brain, CSF sampling
is relatively invasive (when compared with blood sam-
pling) and presents a challenge for large and/or longitu-
dinal studies that involve repeated sampling over time.
Therefore, we developed a system by which p3-Alc
could be quantified in relatively small plasma samples.
The combination of simple p3-Alc extraction and highly
selective ELISA enabled the quantification of p3-Alca in
100 μL of plasma (200 μL in duplicate assay). Successful
extraction of p3-Alca from plasma with chloroform/
methanol solvent suggests that the majority of p3-Alca
in plasma may be bound to lipid or lipoproteins. While
we have not performed further characterization of p3-
Alca in plasma, apolipoprotein E would be a potential
suspect and association could vary by APOE isotype. A
study of the effect of this variable in both CSF and
plasma samples is underway.
We have not yet developed an ELISA system that can
perfectly discriminate levels of each individual p3-Alca
species (e.g., p3-Alca35, p3-Alca38). Such an assay
requires antibodies against the neoepitopes created
when the specific C-termini are generated by g-cleavage.
Since the polyclonal 839 antibody was prepared using
the C-terminal amino acid sequence of p3-Alca35 as
antigen, the ELISA used in this study displayed a relative
specificity for detecting synthetic p3-Alca35, but there
was also crossreactive detection of p3-Alca39 synthetic
peptide at about 50-60% of the sensitivity that was
observed for detection of p3-Alca35 (Figure 1B).
p3-Alca35 with a C-terminal Thr851 is the major
(~90%) peptide among the p3-Alca species with various






AD Total 39 76 ± 7 232 ± 59 378 ± 113
Male 15 74 ± 7 212 ± 54 366 ± 143
Female 24 78 ± 7 245 ± 58 386 ± 92
Normal Total 21 73 ± 6 163 ± 70 254 ± 63
Male 7 71 ± 7 205 ± 19 267 ± 49
Female 14 75 ± 6 142 ± 77 247 ± 69
Average age, gender, and average values of p3-Alca and Ab40 are
summarized. Numbers indicate means ± standard deviation. Details of
individual subjects are shown in Additional file 2, Tables S3 (AD) and S4
(Normal).
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Page 6 of 12Figure 4 Levels of p3-Alca and Ab in plasma from clinical populations (Japanese cohort 2). Plasma samples from AD subjects (n = 39)
and age-matched nondemented controls (n = 21) were analyzed for levels of p3-Alca (A) and Ab40 (B). Total subjects (All, upper panels),
female subjects (Female, middle panels) and male subjects (Male, lower panels) are respectively indicated. Statistical analysis was performed
using the Mann-Whitney U-test. **, P = 0.0017 (A, upper). ***, P = 0.0006 (A, middle). ***, P < 0.0001 (B, upper). ***, P < 0.0001 (B, middle). *, P =
0.0263 (B, lower).
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level of p3-Alca in AD subjects is probably largely
dependent on an increase of p3-Alca35, although we
cannot yet exclude the possibility that another species
such as p3-Alca38 may be selectively increased in AD
subjects [5]. Therefore, in the present study, we could
not examine qualitative changes of p3-Alca species in
plasma. However, we have successfully developed a
potentially useful ELISA for p3-Alc peptides and
demonstrated its utility in the detection and quantifica-
tion of plasma p3-Alca peptide. Despite the fact that
plasma levels of p3-Alca are about ten-fold less than the
levels in CSF, p3-Alca levels are readily quantifiable in
both body fluids using this novel ELISA (Hata et al.,i n
preparation).
Using the novel ELISA specific for p3-Alca,w ef o u n d
that plasma p3-Alca levels were significantly higher in
some AD subjects who also showed higher Ab40 levels.
In female subjects, an obvious and statistically signifi-
cant difference in plasma p3-Alca levels was evident
when AD subjects were compared against age-matched
elderly nondemented controls. The explanation for why
p3-Alca levels and Ab40 levels are higher in some
female AD subjects remains unclear. It is worth noting
that gonadal hormones are known to regulate genera-
tion of Ab [22-24] as well as transcription of the APOE
gene [25]. Similar gender dimorphic results were
recently obtained in plasma samples of another indepen-
dent cohort when the same ELISA system was
employed, suggesting that selection bias is probably not
the explanation for the sex-related differences (Kamo-
gawa et al., in preparation).
Increased levels of plasma Ab and p3-Alca in some
AD subjects may suggest a g-secretase enzymopathy, as
proposed in analyses of CSF p3-Alc [5] and CSF
APLP1-28 [17]. However, we cannot exclude the possi-
bility that p3-Alca clearance may be decreased in AD,
especially since evidence for defective Ab clearance has
been presented by other investigators [18,26]. Analyses
of the possible roles for APOE genotype, CSF and
plasma apoE levels, and CSF and plasma g-secretase and
p3-Alca-degrading enzyme activities are all underway. It
is worth noting that polymorphisms in APOE [27] and
neprilysin [28] have been linked to increased risk of
chronic traumatic encephalopathy and/or AD following
traumatic brain injury [29], and these identical factors
could play similar roles here.
In Japanese cohort 2, we observed higher levels of
plasma Ab40 and p3-Alca. Since p3-Alca peptides are
not deposited in brain or cerebral vessels, the molecular
pathogenesis underlying these changes in CSF and
plasma p3-Alc levels remains unknown. Serial studies of
both plasma and CSF from the same individuals over
time are required in order to elucidate the underpin-
nings of these changes, including the sexual dimorph-
ism. Serial studies of CSF and plasma p3-Alca from
transgenic animals and from subjects in the National
Institute on Aging Alzheimer’sD i s e a s eN e u r o i m a g i n g
Initiative should help clarify these results, and those stu-
dies are also underway.
Figure 5 Diurnal changes of serum p3-Alca levels over a 24 hr
period. Sera of young healthy volunteers (A, 6 males; B, 7 females)
were examined for p3-Alca contents every 8 h within a day.
Sampling times (5 p.m., 1 a.m. and 9 a.m.) are indicated. Clinical
information about the volunteers and values for p3-Alca levels in
sera are described in panel C.
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Page 8 of 12The p3-Alca in blood is likely to be derived from lar-
gely brain because Alca expresses predominantly in
brain neurons [1] and transgenic mice expressing
human Alca-CTF driven by a neuron-specific PDGF
promoter increased p3-Alca levels in plasma (Hata and
Takei, unpublished observation). Alcadein is almost
identical to APP with respect to neural expression, cel-
lular distribution, metabolism, and function [1-4].
Furthermore, we would re-emphasize that p3-Alc does
not aggregate and is stable in plasma, both of which are
desirable qualities in clinical sample preparation and
handling and both of which have complicated analysis
of Ab in bodily fluids. These properties are useful for
the development of sensitive procedures for the detec-
tion of g-secretase dysfunction, and p3-Alca plasma
levels may be useful in identifying AD subjects whose
Figure 6 Correlation between p3-Alca and Ab40 levels in AD and normal subjects (Japanese cohort 2). Correlation of plasma p3-Alca and
Ab levels was explored in AD subjects (A) and normal controls (B). Total subjects (All, upper panels), female subjects (Female, middle panels) and
male subjects (Male, lower panels) are respectively indicated. Statistical analysis was performed by using the Pearson’s correlation coefficient. A.
Upper; r = 0.4405 (P = 0.0050), Middle; r = 0.6149 (P = 0.0014), Lower; r = 0.07328 (P = 0.7952). B. Upper; r = 0.6275 (P = 0.0023), Middle; r =
0.6117 (P = 0.0201), Lower; r = 0.7857 (P = 0.0480).
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Page 9 of 12clinical phenotype is caused by a functional alteration of
g-secretases and/or by defective clearance of transmem-
brane domain-derived peptides. This endophenotyping
may be important for selecting subjects for trials of g-
secretase modulators or plasminogen activator inhibitor-
1 inhibitors [30,31], respectively.
Materials and methods
Blood collection and processing, and quantification of
plasma p3-Alca
Informed consent for the use of all human plasma and
s e r u mi nt h i ss t u d yw a so b t a i n e df r o mt h ep a t i e n t s
and/or their families and approved by the appropriate
ethical boards at each institution. Alzheimer’sd i s e a s e
was clinically diagnosed based on two major criteria;
Diagnostic and Statistical Manual of Mental Disorders:
4th Edition (DSM-IV) and National Institute of Neuro-
logical and Communicational Disorders and Stroke -
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA). In Japanese cohort 1, the clinical
diagnoses of patients with FTLD were made on the
basis of established clinical criteria [32]. A compilation
of clinical characteristics and data is shown in Table 2.
Detailed descriptions of all subjects are shown in Addi-
tional files 2, Tables S1 and S2.
In Japanese cohort 2, all subjects with AD are inpati-
ents and showed MMSE scores consistent with a diag-
nosis of either moderate or severe dementia (CDR 2 or
CDR 3). Clinical characteristics and data are shown in
Table 3. Detailed descriptions of all subjects including
the raw values of p3-Alca are shown in Additional files
2, Tables S3 and S4.
For plasma samples, blood was collected into tubes
containing EDTA and centrifuged. For serum samples,
blood was collected into tubes with no EDTA and
a l l o w e dt oc o a g u l a t e .T oe x t r a c tp 3 - A l c a peptides, a
four-fold volume of organic reagent (800 μL of chloro-
form: methanol [2:1] mixture) was added to plasma or
serum (usually 200 μL for duplicate assay) in a conical
tube (1.5 mL), agitated well by vortexing or sonication
for 10 s, and then left to stand for 1 h at room tempera-
ture (18-23°C). Next, a 160 μL aliquot of distilled water
was added, and the samples were mixed by vortexing.
The samples were centrifuged at 15,000 rpm for 15 min,
and the aqueous phase was recovered and dried using a
SpeedVac system. The dried sample was dissolved in
250 μL of PBS containing 1% (w/v) BSA and 0.05% (v/v)
Tween-20 (buffer A). The samples (×1) or samples
further diluted with buffer A (2- and 4-fold) were used
for ELISA. Aliquots of 100 μL were studied in duplicate.
Generally the undiluted sample (×1) was examined for
quantification.
Antibodies and ELISA system
The major p3-Alca species, p3-Alca35, is a peptide that
includes the sequence from Ala
817 to Thr
852 of Alca1
(for the amino acid sequence of p3-Alca,s e eA d d i t i o n a l
file 1, Figure S1A). Polyclonal rabbit antibodies were
raised against a peptide containing the sequence
between position 817 and 822 (#817 antibody) and a
peptide containing the sequence between position 839
and 852 (#839 antibody), and affinity purified with the
each respective peptide antigen resin. The antibody 839
was used to capture p3-Alca, and horseradish peroxi-
dase-conjugated pan p3-Alca antibody 817 and tetra-
methyl benzidine were used to detect the captured p3-
Alca colormetrically at OD450. Synthetic p3-Alca35 pep-
tide was used as a standard assay protein. The specificity
for p3-Alca in the ELISA was confirmed using synthetic
p3-Alca35 (major species of CSF p3-Alca), p3-Alca39
and p3-Alcb37 peptides [4,5]. Ab in neat samples with-
out extraction was quantified with sELISA (Wako Pure
Chemical Industries Co Ltd for cohort 1 and IBL Co
Ltd for cohort 2).
Additional material
Additional file 1: Figure S1. Amino acid sequences of p3-Alca, and
recovery of p3-Alca in sera by immunoprecipitation and detection
of p3-Alca by Western blotting. A. Amino acid sequences and
cleavage sites of p3-Alca and Ab in human. The amino acid sequences
of p3-Alca species and the primary a- and secondary g-cleavage sites of
Alca1 are indicated. “35” indicates major g-cleavage site to generate p3-
Alca35 while “38” indicates minor g-cleavage site to generate p3-Alca38.
The amino acid sequences of p3 and Ab peptides are also shown.
Primary a- and b- cleavage sites of APP695 are shown, “40” indicates
major g-cleavage site to generate Ab40 while “42” indicates minor g-
cleavage site to generate Ab42. Putative transmembrane region is
indicated with box. B. Detection of endogenous and synthetic p3-Alca
peptides. Synthetic p3-Alca35 peptide (10 ng) was added to human
serum (HS), calf serum (CS), fetal bovine serum (FBS), and bovine serum
albumin solution in PBS (BSA; 10 mg/mL). The samples with (+) or
without (-) addition of p3-Alca35 peptide were subject to
immunoprecipitation with anti-pan p3-Alca 3B5 antibody and
immunoprecipitates were analyzed by Western blotting with UT135
antibody. The far right lane is a loading control sample containing 4 ng
of p3-Alca35 peptide. “Overexposure“ (lower row) indicates overexposure
of film. The pan p3-Alca mouse monoclonal antibody 3B5 and polyclonal
rabbit antibody UT135 have been described (J. Biol. Chem. [2009] 284,
36024-36033). Figure S2. Levels of p3-Alca in plasma of AD and FTLD
subjects (Japanese cohort 1). Plasma samples from AD (n = 49) and
FTLD (n = 15) subjects were analyzed for levels of p3-Alca. Statistical
analysis was performed using the Mann-Whitney U-test. N.S, not
significant. Figure S3. Age, Ab40/42 ratio and MMSE score
distribution in subjects of low and high Ab40 populations
(Japanese cohort 1). Age (upper left), Ab40/42 ratio (upper right) and
MMSE score (lower left) of AD and FTLD subjects of low Ab40
population are compared to these of high Ab40 population. Statistical
analysis was performed using the Mann-Whitney U-test. N.S, not
significant.
Additional file 2: Table S1. Information on AD subjects (Japanese
cohort 1). The subjects (n = 49) were clinically diagnosed using CDR
(clinical dementia rating) criteria. Table S2. Information on FTLD
subjects (Japanese cohort 1). The patients (n = 15) were clinically
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Page 10 of 12diagnosed as described in “Materials and Methods”. Table S3.
Information on AD subjects (Japanese cohort 2). The subjects (n =
39) were clinically diagnosed with AD at stages CDR 2 or CDR 3. Table
S4. Information of normal controls (Japanese cohort 2). Age-
matched normal elderly controls (n = 21) are indicated. The subjects
were clinically non-demented.
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